Table 2

The additive discriminative value of biomarkers of inflammation to the CHA₂DS₂-VASc and HAS-BLED risk scores

Outcome	Inflammatory biomarker	Model	C index without inflammatory biomarker	C index with inflammatory biomarker	p Value
Stroke or systemic embolism	IL-6	CHA₂DS₂-VASc	0.67	0.67	0.1489
	IL-6	CHA₂DS₂-VASc+biomarkers	0.70	0.70	0.6873
	CRP	CHA₂DS₂-VASc	0.67	0.67	0.1917
	CRP	CHA₂DS₂-VASc+biomarkers	0.70	0.70	0.6670
All-cause mortality	IL-6	CHA₂DS₂-VASc	0.63	0.69	<0.0001
	IL-6	CHA₂DS₂-VASc+biomarkers	0.75	0.76	<0.0001
	CRP	CHA₂DS₂-VASc	0.63	0.66	<0.0001
	CRP	CHA₂DS₂-VASc+biomarkers	0.75	0.75	<0.0001
Cardiovascular mortality	IL-6	CHA₂DS₂-VASc	0.64	0.68	<0.0001
	IL-6	CHA₂DS₂-VASc+biomarkers	0.77	0.78	0.0013
	CRP	CHA₂DS₂-VASc	0.64	0.65	<0.0001
	CRP	CHA₂DS₂-VASc+biomarkers	0.77	0.77	0.2708
Major bleed	IL-6	HAS-BLED	0.63	0.65	<0.0001
	IL-6	HAS-BLED+biomarkers	0.68	0.68	0.0689
	CRP	HAS-BLED	0.63	0.63	0.1439
	CRP	HAS-BLED+biomarkers	0.68	0.68	0.2819

The first model contains the CHA₂DS₂-VASc risk score or the HAS-BLED risk score for major bleeding outcomes, in addition to randomised treatment, region, use of warfarin within 7 days before randomisation, use of statin medication within 30 days before randomisation. The second model contains, in addition to the variables in the first model, the cardiovascular and renal biomarkers (NT-proBNP, Troponin I, GDF-15 and cystatin C).
CRP, C reactive protein.